Akeso's Ivonescimab Achieves Positive OS Results in Phase III First-Line Biliary Tract Cancer Trial
Nashnova编辑部
Akeso announced that its bispecific antibody ivonescimab met the overall survival (OS) primary endpoint in a Phase III trial for first-line advanced biliary tract cancer — marking the drug's first positive Phase III result outside lung cancer and validating its expansion into gastrointestinal tumors.
What exactly did this trial prove?
Trial AK112-309 enrolled 682 patients with advanced biliary tract cancer in a randomized, double-blind, controlled design — the gold standard for regulatory approval.
Ivonescimab plus chemotherapy was tested against durvalumab (a PD-L1 inhibitor) plus chemotherapy. The Independent Data Monitoring Committee (IDMC) confirmed at a pre-specified interim analysis: the OS primary endpoint was met with statistically significant and clinically meaningful benefit.
In plain terms = compared with the current standard regimen, patients on ivonescimab lived longer — and the gap was too large to be coincidence.
Why is this result especially important for ivonescimab?
Ivonescimab is the world's first PD-1/VEGF bispecific antibody — a drug that blocks two tumor-growth pathways at once. All 4 prior Phase III wins were in lung cancer.
This means → the biliary tract cancer data is ivonescimab's first Phase III positive outside the lungs, proving the dual-target mechanism works beyond one organ and extending the expansion logic toward a broader class of solid tumors.
The trial also hit progression-free survival (PFS) and objective response rate (ORR) — all key secondary endpoints positive. A clean sweep strengthens the regulatory filing package.
How many approved indications does ivonescimab already hold?
China's NMPA has approved three indications, all in lung cancer: May 2024 for second-line EGFR-mutant non-squamous NSCLC; April 2025 for first-line PD-L1-positive advanced NSCLC; August 2026 for first-line squamous NSCLC.
Two of those lung cancer indications are already on the national reimbursement list. This reflects a drug already in its commercial ramp-up phase for lung cancer.
In plain terms = lung cancer is the "established brand already generating revenue"; biliary tract cancer is "the new front that just got its report card."
What comes next?
Ivonescimab is being studied across more than 40 indications — biliary tract, head-and-neck squamous, triple-negative breast, colorectal, pancreatic, and urothelial cancers among them — with 60 Phase II/III trials underway, of which 16 are registrational.
This means → if the biliary tract cancer indication clears approval and wins reimbursement, it creates a template for the GI and broader solid-tumor pipeline behind it.
Full data have not yet been disclosed and will be presented at future international conferences and in journals — data quality and safety details are still pending, and the market's pricing of commercialization potential will only sharpen once those numbers are public.
Content is for reference only, not financial advice.